A modified yeast assay used on archival samples of localized prostate cancer tissue improves the detection of p53 abnormalities and increases their predictive value

BJU International

Volumn 94, Issue 7, 2004, Pages 996-1002

  Shi, Xu Bao ^a   Gandour Edwards, Regina ^a   Beckett, Laurel A ^a   Deitch, Arline D ^a   De Vere White, Ralph W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immunohistochemistry; p53 mutation; Primary prostate cancer; Yeast functional assay

Indexed keywords

ADULT; AGED; ARTICLE; BIOASSAY; CANCER GROWTH; CANCER LOCALIZATION; CANCER MORTALITY; CLINICAL PROTOCOL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DNA SEQUENCE; EXON; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; MALE; MODIFIED YEAST FUNCTIONAL ASSAY; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; TISSUE SECTION; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BIOLOGICAL ASSAY; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; YEASTS;

EID: 9644290844     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.05093.x     Document Type: Article

References (30)

1. Aprikian AG, Sarkis AS, Fair WR, Zhang ZF, Fuks Z, Cordon-Cardo C. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol 1994; 151: 1276-80
2. Heidenberg HB, Sesterhenn IA, Gaddipati JP et al. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 1995; 154: 414-21
3. Meyers FJ, Gumerlock PH, Chi SG, Borchers H, Deitch AD, deVere White RW. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer 1998; 83: 2534-9
4. Bookstein R, MacGrogan D, Hilsenbeck SG, Sharkey F, Allred DC. p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 1993; 53: 3369-73
5. Mottar AE, Markwalder R, Fey MF et al. Abnormal p53 expression is rare in clinically localized human prostate cancer, comparison between immunohistochemical and molecular detection of p53 mutations. Prostate 1997; 31: 209-15
6. Heidenberg HB, Bauer JJ, McLeod DG, Moul JW, Srivastava S. The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker? Urology 1996; 48: 971-9
7. Chi SG, deVere White RW, Meyers FJ, Siders DB, Lee F, Gumerlock PH. p53 in prostate cancer: frequent expressed transition mutations. J Natl Cancer Inst 1994; 86: 926-33
8. Downing SR, Jackson P, Russell PJ. Mutations within the tumor suppressor gene p53 are not confined to a late event in prostate cancer progression. a review of the evidence. Urol Oncol 2001; 6: 103-10
9. Grignon DJ, Caplan R, Sarkar FH et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. J Natl Cancer Inst 1997; 89: 158-65
10. Grossfeld GD, Olumi AF, Connolly JA et al. Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity. J Urol 1998; 159: 1437-43
11. Merseburger AS, Kuczyk MA, Serth J et al. Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. Oncol Rep 2003; 10: 223-8
12. Berthon P, Dimitrov T, Stower M, Cussenot O, Maitland NJ. A microdissection approach to detect molecular markers during progression of prostate cancer. Br J Cancer 1995; 72: 946-51
13. Mirchandani D, Zheng J, Miller GJ et al. Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. Am J Pathol 1995; 147: 92-101
14. Shi XB, Nesslinger NJ, Deitch AD, Gumerlock PH, deVere White RW. Complex functions of mutant p53 alleles from human prostate cancer. Prostate 2002; 51: 59-72
15. Nesslinger NJ, Shi XB, deVere White RW. Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53. Cancer Res 2003; 63: 2228-33
16. Pirollo KF, Bouker KB, Chang EH. Does p53 status influence tumor response to anticancer therapies? Anticancer Drugs 2000; 11: 419-32
17. Downing SR, Russell PJ, Jackson P. Alterations of p53 are common in early stage prostate cancer. Can J Urol 2003; 10: 1924-33
18. Shi XB, Di Mauro SM, Highshaw R et al. Application of a yeast assay to detect functional p53 mutations in archival prostate cancer tissue. Cancer Biother Radiopharm 2002; 17: 657-64
19. Flaman JM, Frebourg T, Moreau V et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 1995; 92: 3963-7
20. Shi XB, Bodner SM, deVere White RW, Gumerlock PH. Identification of p53 mutations in archival prostate tumors. Sensitivity of an optimized single-strand conformational polymorphism (SSCP) assay. Diagn Mol Pathol 1996; 5: 271-8
21. Inga A, Monti P, Fronza G, Darden T, Resnick MA. p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay. Oncogene 2001; 20: 501-13
22. Jhaveri FM, Zippe CD, Klein EA, Kupelian PA. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology 1999; 54: 884-90
23. Oxley JD, Winkler MH, Parry K, Brewster S, Abbott C, Gillatt DA. p53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy. BJU Int 2002; 89: 27-32
24. Stackhouse GB, Sesterhenn IA, Bauer JJ et al. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 1999; 162: 2040-5
25. Lee SO, Lou W, Hou M, de Miguel F, Gerber L, Gao AC. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clin Cancer Res 2003; 9: 370-6
26. Culig Z, Bartsch G, Hobisch A. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol Cell Endocrinol 2002; 197: 231-8
27. Corcoran NM, Costello AJ. Interleukin-6: minor player or starring role in the development of hormone-refractory prostate cancer? BJU Int 2003; 91: 545-53
28. Kung HJ, Tepper CG, deVere White RW. Tyrosine kinases and cellular signaling in prostate cancer. In Chung LWK, Isaacs WB, Simons JW eds, Prostate Cancer: Biology, Genetics, and the New Therapeutics, Chapt 15. Totowa, NJ: Humana Press Inc. 2000: 241-66
29. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW. Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 1995; 45: 542-9
30. Akakura K, Suzuki H, Ueda T et al. Possible mechanism of dexamethasone therapy for prostate cancer: suppression of circulating level of interleukin-6. Prostate 2003; 56: 106-9